Huons Meditech, a medical device subsidiary of Huons Group, announced on November 19th that it held strategic discussions with its Indian partner on local assembly production and global business expansion.

Huons Meditech (CEO Changwoo Ha) recently invited senior executives from Vasu Group to Korea to outline detailed strategies for entering the Indian market. Vasu Group, founded in 1985, operates a nationwide pharmaceutical and medical device distribution network across Telangana, Andhra Pradesh, and other regions. The two companies first signed a partnership agreement in March, and the latest meeting was held to refine concrete execution plans.

During the discussions, the companies reviewed business strategies centered on the CKD (Complete Knock Down) model for local assembly. Huons Meditech presented updates on the global supply status and technology roadmap of its extracorporeal shockwave lithotriptors, as well as the 2025 production plans and overseas rollout schedule for its endoscope reprocessors.

Vasu Group highlighted the importance of localized production for the endoscope reprocessor portfolio—an area where India prioritizes domestically produced devices—and noted the complex regulatory requirements associated with medical device registration.

Both sides agreed that introducing CKD-based production in India would provide substantial advantages, including stronger price competitiveness, improved logistics efficiency, lower regulatory risks, and faster market penetration.

Huons Meditech CEO Changwoo Ha stated, “The CKD model in India will serve as a key pillar of Huons Meditech’s global expansion strategy for 2026. We will continue to strengthen our partnership with Vasu Group, particularly in extracorporeal shockwave lithotriptors, endoscope reprocessors, and disinfectant products, to accelerate entry into global markets.”

Huons Meditech plans to further solidify the CKD collaboration model for India and expedite its overseas expansion based on this strategic partnership.